Apnimed, Inc. (APMD) News
Follow Apnimed, Inc. (APMD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Apnimed Q2 2026 net income $125.9M; Oxnimbi PDUFA Feb 28, 2027
Apnimed reported Q2 2026 net income of $125.9M and ended the quarter with $172.8M in cash and cash equivalents. FDA accepted its NDA for AD109 (proposed Oxnimbi) with a PDUFA target date of Feb 28, 2027.
EARNINGS | Sep 08, 2026, 09:23 PM UTC
M
APMD net income rises to $193.7M in H1 2026
APMD reported net income of $193.7M for the first half of 2026, driven by SASS divestiture gains. R&D expenses fell as Phase 3 trials for Oxnimbi concluded. Cash was $172.8M pre-IPO and $200.4M raised in August.
EQUITY | Sep 08, 2026, 09:16 PM UTC
M
Apnimed posts 2Q net $125.9M
Apnimed reported 2Q net income of $125.9M.
EQUITY | Sep 08, 2026, 08:40 PM UTC
L
Apnimed reports Q2 2026 financial results and corporate update
Apnimed (APMD) reports second-quarter 2026 financial results and provides a corporate update.
EARNINGS | Sep 08, 2026, 08:39 PM UTC
L
Apnimed reports inducement grants under Nasdaq Rule 5635(c)(4)
Apnimed, Inc. reports inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 08:01 PM UTC
M
Apnimed Closes Upsized IPO
Apnimed closes upsized initial public offering
EQUITY | Aug 03, 2026, 08:35 PM UTC
L
APMD APMD - Apnimed Announces Pricing of Upsized Initial Public Offering
APMD APMD - Apnimed Announces Pricing of Upsized Initial Public Offering
EQUITY | Jul 31, 2026, 02:10 AM UTC